Fortress Biotech (FBIO) closed at $1.88 on November 13, 2026, down 5.5% from the previous close, on volume of 309,573 shares (30-day average 230,655).
Data as of November 13, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Fortress Biotech Earnings Call Highlights Emrosi Momentum
TipRanks (Sun, 15-Nov 12:39 AM ET)
Fortress Biotech GAAP EPS of -$0.23 beats by $0.04, revenue of $19.16M misses by $2.41M
Seeking Alpha News (Fri, 13-Nov 8:13 AM ET)
Fortress Biotech Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
Globe Newswire (Fri, 13-Nov 8:00 AM ET)
Globe Newswire (Thu, 12-Nov 4:01 PM ET)
Here are the major earnings after the close Thursday
Seeking Alpha News (Thu, 12-Nov 10:00 AM ET)
Globe Newswire (Tue, 10-Nov 4:05 PM ET)
Journey Medical Corporation to Announce Third Quarter 2026 Financial Results on November 12, 2026
Globe Newswire (Thu, 5-Nov 8:30 AM ET)
Journey Medical Corporation to Participate in September 2026 Investor Conferences
Globe Newswire (Tue, 8-Sep 4:05 PM ET)
Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Globe Newswire (Tue, 8-Sep 8:00 AM ET)
Market Chameleon (Mon, 23-Feb 4:56 AM ET)
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
Fortress Biotech trades on the NASDAQ stock market under the symbol FBIO.
As of November 16, 2026, FBIO stock price declined to $1.84 with 52,328 million shares trading.
FBIO has a beta of 0.59, meaning it tends to be less sensitive to market movements. FBIO has a correlation of 0.02 to the broad based SPY ETF.
FBIO has a market cap of $61.37 million. This is considered a Micro Cap stock.
Last quarter Fortress Biotech reported $19 million in Revenue and -$.23 earnings per share. This fell short of revenue expectation by $-2 million and exceeded earnings estimates by $.04.
In the last 3 years, FBIO traded as high as $4.53 and as low as $1.29.
The top ETF exchange traded funds that FBIO belongs to (by Net Assets): VTI, VXF, IWC, BSVO, AVSC.
FBIO has underperformed the market in the last year with a price return of -26.1% while the SPY ETF gained +12.0%. FBIO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -38.3% and -4.2%, respectively, while the SPY returned -4.0% and -1.4%, respectively.
FBIO support price is $1.81 and resistance is $1.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FBIO shares will trade within this expected range on the day.